Pacific Shuanglin Bio-pharmacy Co., LTD (SHE: 000403)

Market Cap	17.62B
Revenue (ttm)	2.76B
Net Income (ttm)	795.96M
Shares Out	731.07M
EPS (ttm)	1.09
PE Ratio	22.10
Forward PE	20.78
Dividend	0.20 (0.82%)
Ex-Dividend Date	Jun 28, 2024

Volume	1,979,218
Open	24.94
Previous Close	24.31
Day's Range	24.06 - 24.94
52-Week Range	18.19 - 31.25
Beta	0.48
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2024

About Pacific Shuanglin Bio-pharmacy Co., LTD

Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in research, development, production, and sales of blood products in China. Its lead products include human serum albumin, human immunoglobulin, intravenous human immunoglobulin (PH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies patient immunoglobulin, and human coagulation factor. addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; and electronic product information consultation. The c...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 2,426
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000403

Financial Performance

In 2023, Pacific Shuanglin Bio-pharmacy Co., LTD's revenue was 2.33 billion, a decrease of -3.18% compared to the previous year's 2.41 billion. Earnings were 612.11 million, an increase of 4.25%.